-
EP3178490
European procedure
Extract from the Register of European Patents
EP About this file: EP3178490
| EP3178490 - RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME [Right-click to bookmark this link] | Status | The patent has been granted Status updated on 18.03.2022 Database last updated on 03.05.2025 | |
| Former | Grant of patent is intended Status updated on 03.11.2021 | ||
| Former | Examination is in progress Status updated on 29.06.2018 | ||
| Former | Request for examination was made Status updated on 12.05.2017 | Most recent event Tooltip | 26.04.2025 | New entry: Date of oral proceedings | Applicant(s) | For all designated states GlaxoSmithKline Biologicals S.A. Rue de l'Institut, 89 1330 Rixensart / BE | [2017/24] | Inventor(s) | 01 /
SWANSON, Kurt c/o Novartis Vaccines and Diagnostics, Inc. IP Services M/S X-100B P.O. Box 8097 Emeryville, CA 94662-8097 / US | 02 /
DORMITZER, Philip, R. c/o Novartis Vaccines and Diagnostics, Inc. IP Services M/S X-100B P.O. Box 8097 Emeryville, CA 94662-8097 / US | [2017/24] | Representative(s) | J A Kemp LLP 80 Turnmill Street London EC1M 5QU / GB | [N/P] |
| Former [2017/24] | Thornley, Rachel Mary, et al GlaxoSmithKline Global Patents (CN925.1) 980 Great West Road Brentford, Middlesex TW8 9GS / GB | Application number, filing date | 16190004.8 | 15.07.2010 | [2017/24] | Priority number, date | US20090225805P | 15.07.2009 Original published format: US 225805 P | US20100294426P | 12.01.2010 Original published format: US 294426 P | [2017/24] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | EP3178490 | Date: | 14.06.2017 | Language: | EN | [2017/24] | Type: | A3 Search report | No.: | EP3178490 | Date: | 30.08.2017 | Language: | EN | [2017/35] | Type: | B1 Patent specification | No.: | EP3178490 | Date: | 20.04.2022 | Language: | EN | [2022/16] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 28.07.2017 | Classification | IPC: | A61K39/155, C07K14/135, C07K16/10 | [2017/24] | CPC: |
C07K16/1027 (EP,US);
A61K39/12 (EP,US);
A61K39/155 (EP,US);
A61P11/00 (EP);
A61P31/14 (EP);
A61P37/04 (EP);
C07K14/005 (EP,US);
A61K2039/5252 (EP,US);
A61K2039/5256 (EP,US);
A61K2039/5258 (EP,US);
A61K2039/53 (EP,US);
A61K2039/55505 (EP,US);
A61K2039/55555 (EP,US);
A61K2039/55561 (EP,US);
A61K2039/55566 (EP,US);
A61K2039/55572 (EP,US);
A61K39/00 (EP,US);
C07K2317/76 (EP,US);
C07K2319/00 (EP,US);
C07K2319/21 (EP,US);
C07K2319/50 (EP,US);
C07K2319/73 (EP,US);
C12N2760/18522 (EP,US);
C12N2760/18534 (EP,US);
C12N2770/36143 (EP,US)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR [2017/24] | Title | German: | RSV-F-PROTEINZUSAMMENSETZUNGEN UND VERFAHREN ZU IHRER HERSTELLUNG | [2017/24] | English: | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | [2017/24] | French: | COMPOSITIONS À BASE DE PROTÉINE F DU VRS ET PROCÉDÉS DE FABRICATION ASSOCIÉS | [2017/24] | Examination procedure | 21.09.2016 | Examination requested [2017/24] | 21.09.2016 | Date on which the examining division has become responsible | 28.02.2018 | Amendment by applicant (claims and/or description) | 02.07.2018 | Despatch of a communication from the examining division (Time limit: M06) | 17.04.2019 | Reply to a communication from the examining division | 16.08.2019 | Despatch of a communication from the examining division (Time limit: M06) | 20.03.2020 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time | 26.05.2020 | Reply to a communication from the examining division | 28.09.2021 | Date of oral proceedings | 25.10.2021 | Minutes of oral proceedings despatched | 04.11.2021 | Communication of intention to grant the patent | 14.03.2022 | Fee for grant paid | 14.03.2022 | Fee for publishing/printing paid | 14.03.2022 | Receipt of the translation of the claim(s) | Parent application(s) Tooltip | EP10734875.7 / EP2453918 | EP15200194.7 | Divisional application(s) | EP21199223.5 / EP3988115 | EP22181400.7 Application withdrawn : 24.11.2022 | EP22181401.5 Application withdrawn : 24.11.2022 | EP22200670.2 / EP4183412 | EP22214601.1 / EP4218799 | EP22214608.6 / EP4218800 | Opposition(s) | Opponent(s) | 01
19.01.2023
20.01.2023
ADMISSIBLE Janssen Vaccines & Prevention B.V. Archimedesweg 4-6 2333 CN Leiden / NL Opponent's representative Boult Wade Tennant LLP Salisbury Square House 8 Salisbury Square London EC4Y 8AP / GB | 02
20.01.2023
07.04.2025
WITHDRAWN Pfizer Inc. 66 Hudson Boulevard East New York, NY 10001-2192 / US Opponent's representative Pfizer European Patent Department 23-25 avenue du Docteur Lannelongue 75668 Paris Cedex 14 / FR | [2025/20] |
| Former [2023/26] | |||
| Opponent(s) | 01
19.01.2023
20.01.2023
ADMISSIBLE Janssen Vaccines & Prevention B.V. Archimedesweg 4-6 2333 CN Leiden / NL Opponent's representative Boult Wade Tennant LLP Salisbury Square House 8 Salisbury Square London EC4Y 8AP / GB | ||
| 02
20.01.2023
23.01.2023
ADMISSIBLE Pfizer Inc. 66 Hudson Boulevard East New York, NY 10001-2192 / US Opponent's representative Pfizer European Patent Department 23-25 avenue du Docteur Lannelongue 75668 Paris Cedex 14 / FR | |||
| Former [2023/10] | |||
| Opponent(s) | 01
19.01.2023
20.01.2023
ADMISSIBLE Janssen Vaccines & Prevention B.V. Archimedesweg 4-6 2333 CN Leiden / NL Opponent's representative Boult Wade Tennant LLP Salisbury Square House 8 Salisbury Square London EC4Y 8AP / GB | ||
| 02
20.01.2023
23.01.2023
ADMISSIBLE Pfizer Inc. 235 East 42nd Street New York, NY 10017 / US Opponent's representative Pfizer European Patent Department 23-25 avenue du Docteur Lannelongue 75668 Paris Cedex 14 / FR | |||
| Former [2023/09] | |||
| Opponent(s) | 01
19.01.2023
20.01.2023
ADMISSIBLE Janssen Vaccines & Prevention B.V. Archimedesweg 4-6 2333 CN Leiden / NL Opponent's representative Boult Wade Tennant LLP Salisbury Square House 8 Salisbury Square London EC4Y 8AP / GB | ||
| 02
20.01.2023
Pfizer Inc. 235 East 42nd Street New York, NY 10017 / US Opponent's representative Pfizer European Patent Department 23-25 avenue du Docteur Lannelongue 75668 Paris Cedex 14 / FR | 03.02.2023 | Invitation to proprietor to file observations on the notice of opposition | 14.08.2023 | Reply of patent proprietor to notice(s) of opposition | 05.02.2026 | Date of oral proceedings | Request for further processing for: | The application is deemed to be withdrawn due to failure to reply to the examination report | 26.05.2020 | Request for further processing filed | 26.05.2020 | Full payment received (date of receipt of payment) Request granted | 04.06.2020 | Decision despatched | The application is deemed to be withdrawn due to failure to reply to the examination report | 17.04.2019 | Request for further processing filed | 17.04.2019 | Full payment received (date of receipt of payment) Request granted | 02.05.2019 | Decision despatched | Fees paid | Renewal fee | 21.09.2016 | Renewal fee patent year 03 | 21.09.2016 | Renewal fee patent year 04 | 21.09.2016 | Renewal fee patent year 05 | 21.09.2016 | Renewal fee patent year 06 | 21.09.2016 | Renewal fee patent year 07 | 10.07.2017 | Renewal fee patent year 08 | 10.07.2018 | Renewal fee patent year 09 | 09.07.2019 | Renewal fee patent year 10 | 10.07.2020 | Renewal fee patent year 11 | 20.07.2021 | Renewal fee patent year 12 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | AL | 20.04.2022 | MC | 20.04.2022 | MK | 20.04.2022 | SM | 20.04.2022 | GB | 27.03.2023 | [2024/30] |
| Former [2024/22] | AL | 20.04.2022 | |
| MK | 20.04.2022 | ||
| SM | 20.04.2022 | ||
| GB | 27.03.2023 | ||
| Former [2023/47] | AL | 20.04.2022 | |
| SM | 20.04.2022 | ||
| GB | 27.03.2023 | ||
| Former [2023/17] | AL | 20.04.2022 | |
| SM | 20.04.2022 | ||
| Former [2023/10] | SM | 20.04.2022 | Documents cited: | Search | [A]WO03083095 (AKZO NOBEL NV [NL], et al); | [XYA]WO2009079796 (ID BIOMEDICAL CORP QUEBEC [CA], et al); | [PA]WO2010009277 (NOVARTIS AG [CH], et al); | [PI]WO2010077717 (NOVAVAX INC [US], et al); | by applicant | US4186745 | EP0109942 | US4666886 | US4680338 | US4689338 | US4797368 | GB2220211 | US4929624 | WO9014837 | US4988815 | US5011828 | WO9106309 | US5057540 | WO9215582 | US5173414 | US5238944 | WO9319780 | US5266575 | US5268376 | WO9324640 | WO9324641 | WO9400153 | US5279833 | US5340740 | US5346905 | WO9421292 | US5352784 | EP0626169 | US5389640 | US5395937 | US5397307 | WO9511700 | WO9517211 | WO9517210 | US5482936 | US5494916 | WO9611711 | US5525612 | US5547472 | WO9626741 | WO9633739 | US5656479 | US5658731 | US5674192 | WO9840100 | WO9842375 | US5830510 | WO9927960 | US5916588 | US5936076 | WO9952549 | WO9962923 | WO0007621 | WO0023105 | US6060308 | US6071890 | US6080725 | US6083741 | US6083505 | US6090619 | US6090406 | US6114168 | US6129705 | US6207646 | WO0121207 | WO0121152 | WO0122972 | US6239116 | WO0195935 | WO0218383 | US6355271 | WO0226757 | US6429199 | US6440992 | EP0787180 | US6500668 | WO03011223 | WO03035836 | WO03043415 | US6586409 | US6605617 | WO03076601 | US6627640 | WO03082272 | US6664264 | US6664265 | US6667312 | WO03105769 | US6677347 | US6677348 | US6677349 | US6683088 | WO2004018455 | US6703402 | US6743920 | WO2004060308 | WO2004064715 | WO2004064759 | US6800624 | WO2004087153 | US6809203 | FR2859633 | US2005070556 | US6888000 | WO2005042728 | US6924293 | US6924271 | US2005192248 | US2005215517 | WO2005097181 | WO2005102049 | WO2006002422 | WO2006011060 | US2008057080 | US2008085870 | WO2009111337 | WO2009132206 | WO1994US05700 | EP20030291813 | Opposition | WO2009079796 | WO2009128951 | WO2011008974 |